Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Oppenheimer's Rating of Avalo Therapeutics on 10/26/2026

On October 26, 2026, Oppenheimer updated its outlook on Avalo Therapeutics (NASDAQ:AVTX) with the action "Set Price Target", setting a price target of $16.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Oppenheimer Holdings, Inc.

DateCompanyAction
10/26/2026
MSC Income Fund stock logo
MSIF
MSC Income Fund
Initiated Coverage
10/26/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Reiterated Rating
10/26/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Set Price Target
10/26/2026
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Downgrade
10/26/2026
Datadog, Inc. stock logo
DDOG
Datadog
Boost Price Target
10/26/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Boost Price Target
More Ratings From Oppenheimer Holdings, Inc.